Table 1.
Overview of individuals at baseline used in this study.
| pSS | HC | |
|---|---|---|
| Characteristics | ||
| Number | 52 | 20 |
| Age in years (mean ± SD) | 47.7 ± 11.3 | 46.8 ± 12.0 |
| Range | 20-68 | 24-77 |
| Female : male | 49 : 3 | 19 : 1 |
| Clinical features | ||
| ANA+ (%) | 44 (84.6) | 0 (0) |
| Ro/SSA+ (%) | 44 (84.6) | NA |
| La/SSB+ (%) | 23 (44.2) | NA |
| ESR, high levels (>20 mm/h) (%) | 25 (48.1) | NA |
| CRP, high levels (>5 mg/l) (%) | 7 (13.5) | NA |
| IgG, elevated levels (>16 g/l) (%) | 26 (50) | NA |
| Focus score ≥ 1 (%) | 42 (87.5)a | NA |
| ESSDAI range (median) | 0-15 (4) | NA |
Categorical data are expressed as the absolute frequency, with percentages in parenthesis. ANA: antinuclear antibodies; Ro/SSA+: antibodies against Ro/Sjögren's syndrome A antigen; La/SSB+: antibodies against La/Sjögren's syndrome B antigen; ESR: erythrocyte sedimentation rate; CRP: C-reactive protein; focus score indicates the number of inflammatory foci containing more than 50 mononuclear cells per 4 mm2 biopsy tissue. ESSDAI: EULAR Sjögren's Syndrome Disease Activity Index; NA: not applicable. an = 48.